Andrew Henry Matthews, MD

Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M. Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response , Leukemia: 2025

Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C. Evolving racial/ethnic disparities in AML survival in the novel therapy era , Blood Adv, 9(3): 2025,533-544

Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol, 114(4): 2024,626-635

Takeshi Onoue, Andrew H Matthews, Azin Vakilpour, Yu Kang, Bénédicte Lefebvre, Amanda M Smith, Shannon R McCurdy, Michael G Fradley, Joseph Carver, Jesse Chittams, Marielle Scherrer-Crosbie Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines , Cardio-Oncology, 10(1): 2024

Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander E Perl, David L Porter, Arlene Zeringue, Joseph H Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia , Haematologica, 8(109): 2024,2732-2737

Laczko D, Poveda-Rogers C, Matthews AH, Snaith O, Luger S, Bagg A, Caponetti GC, Morrissette JJD, Yang G. RAD21 mutations in acute myeloid leukemia , Leuk & Lymphoma, 65(7): 2024,958-964

Matthews A, Fenu E, Skuli SJ, Harris JC, Lai C. Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach. , Leuk & Lymphoma, 65(7): 2024,1012-1015

Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol, 114(4): 2024,626-635

Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, Geramita EM, Kota VK, Swaroop A, Doukas P, Bradshaw D, Helenowski IB, Liu Y, Zhang H, Im A, Litzow MR, Perl AE, Atallah E, Altman JK. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers , Am J Hematol, 99(4): 2024

Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia , Am J Hematol, 98(8): 2023,1254-1264